{"id":"W4283328999","doi":"10.1097/01.hs9.0000843512.62237.dc","title":"S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Bosutinib; Discontinuation; Tolerability; Internal medicine; Adverse effect; Imatinib; Myeloid leukemia; Nilotinib; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004719673,0.0006852962,0.001281011,0.000290082,0.0001598394,0.00002960301,0.0002635646,0.0001715018,0.001402978],"category_scores_gemma":[0.0001498036,0.0006139732,0.0001034164,0.00104151,0.0001769225,0.0002474156,0.0004665402,0.0009309865,0.00002436377],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0125013,"about_ca_system_score_gemma":0.002972149,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002193982,"about_ca_topic_score_gemma":0.002849563,"domain_scores_codex":[0.9948182,0.0003231375,0.001549733,0.001386655,0.00106518,0.0008571567],"domain_scores_gemma":[0.9975198,0.0002329968,0.0005574384,0.001256175,0.0001055246,0.0003280454],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4550198,0.07333038,0.2786731,0.001404988,0.001719124,0.007328571,0.02295156,0.003784001,0.004954127,0.00001380729,0.003133817,0.1476868],"study_design_scores_gemma":[0.6287124,0.03445343,0.3225434,0.001613406,0.0005062876,0.00002810455,0.001287021,0.001621094,0.002966854,0.000006518664,0.005372928,0.0008885365],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917406,0.002452806,0.000003527632,0.0001465599,0.0001670938,0.004489155,0.0007993522,0.00007653538,0.000124393],"genre_scores_gemma":[0.9974115,0.0001063434,0.0002340408,0.0001012823,0.0002085088,0.0005080762,0.001095499,0.0001266116,0.0002081574],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1736926,"threshold_uncertainty_score":0.9996312,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01020433407372738,"score_gpt":0.2673810174070419,"score_spread":0.2571766833333145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}